Yesterday the New York Daily News reported that A-Rod and Major League Baseball were discussing a plea deal that would land him a 150-game suspension in lieu of gambling over a potential lifetime ban in the event he took an appeal of any Biogenesis-related discipline to arbitration. The report described a shaken A-Rod following his meeting with Major League Baseball on Friday.
Later in the day, however, his team denied the report:
We’re into he-said, he-said land. Or he-said, he-didn’t-say. It’s pretty impossible to know what’s really going on here given all of the agendas at play. MLB is obviously getting tough and is trying to send messages, but they also want to be seen being tough and sending a message, so it may lend itself to leaks and reports that aren’t exactly on the mark. Meanwhile, A-Rod and other players want to defend themselves — and to be seen as defending themselves so that maybe players don’t think they’re wavering — but they could still be trying to mitigate the fallout if MLB’s case against them is strong.
The most significant thing about plea deal talk? The idea that there can be plea deals in the context of a drug testing/punishment regime that is supposed to be an exercise in zero-tolerance and mechanical justice. A program that isn’t supposed to be about negotiation and leverage because such things introduce uncertainty into a program that isn’t supposed to carry any, by design.
Maybe the unique circumstances of the Biogenesis case necessitate that. But I feel like baseball’s drug program is going to be permanently affected by what transpires before this is all said and done.
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.